Current hepatitis E virus seroprevalence in Swiss blood donors and apparent decline from 1997 to 2016.

Conclusions: HEV seroprevalence in Switzerland is high, but has declined over the last decades. The result shows that primarily endemic HEV infections occur and that current blood products may pose a risk to vulnerable transfusion recipients. Nucleic acid screening of all blood products for HEV will begin in November 2018. PMID: 30180927 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/30180927?dopt=Abstract

Source: Euro Surveill - August 1, 2018 Category: Infectious Diseases Authors: Niederhauser C, Widmer N, Hotz M, Tinguely C, Fontana S, Allemann G, Borri M, Infanti L, Sarraj A, Sigle J, Stalder M, Thierbach J, Waldvogel S, Wiengand T, Züger M, Gowland P Tags: Euro Surveill Source Type: research